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During the 2015 European Respiratory Society Congress, a symposiumwas held on ‘Current thinking and
new paradigm for COPD’. Through a combination of plenary lectures and interactive panel discussions,
experts discussed the recent evidence for chronic obstructive pulmonary disease (COPD) treatment and
how this evidence can be applied in clinical practice.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The aims of chronic obstructive pulmonary disease (COPD)
treatment are to alleviate symptoms and reduce future risks. At the
‘Current thinking and new paradigm for COPD’ symposium, held on
28 September at the 2015 European Respiratory Society Congress in
Amsterdam, The Netherlands, respiratory experts discussed how
our current understanding of optimal treatment approaches and
the potential future of COPD management can help physicians to
meet these goals.
Through plenary lectures and interactive panel discussions, the
expert faculty took delegates on a journey through the COPD
treatment paradigm, highlighting current thinking and future
perspectives in the ﬁeld. They explored the rationale for combining
classes of bronchodilators (the cornerstone of COPD treatment),
and the efﬁcacy and safety of dual bronchodilator combinations.
The faculty also discussed the prevention of COPD exacerbations,
including the beneﬁts and risks associated with the use of inhaled
corticosteroids in COPD management. Clinical evidence presented
throughout the symposium was translated into real-life patient
case studies, which reviewed how data from clinical trials can be
applied in real-life practice. Key issues in COPD management were
further explored during several lively panel discussions.
The full symposium can be viewed at the link provided below.(T. Welte), ken.chapman.
agnussen@pulmoresearch.de
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